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pemetrexed arm compared to 0.62 for the gemcitabine arm. The total cost per patient 
was a20,438 for pemetrexed/cisplatin and a17,605 for gemcitabine/cisplatin. These 
model outputs result in incremental cost-effectiveness ratios of a24,507 per LYG, and 
a48,666 per QALY gained. Univariate sensitivity analyses show that the results are 
most sensitive to overall survival. CONCLUSIONS: For oncolytics in Italy, a70,000/
QALY is often considered a good indication of willingness-to-pay threshold. Accord-
ing to the model, pemetrexed/cisplatin is a cost-effective alternative to gemcitabine/
cisplatin in the ﬁrst-line treatment of NSCLC patients within the adenocarcinoma 
population.
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OBJECTIVES: A multicenter randomized phase III trial (study 304820) showed 
patients with stage III or IV follicular lymphoma who achieved a partial or complete 
response after ﬁrst-line treatment wtih 90Y-ibritumomab tiuxetan had signiﬁcantly 
longer PFS time than patients receiving no treatment. The objective of this study is to 
compare costs and outcomes of subsequent treatment with a course of 90Y-ibritu-
momab tiuxetan compared with no treatment in patients with complete or partial 
response following ﬁrst-line chemotherapy from a Spanish payer perspective.
METHODS: A lifetime Markov model was developed to compare 90Y-ibritumomab 
tiuxetan consolidation therapy vs. ‘no consolidation’. The model consists of four 
states: progression-free with complete response (CR), progression-free with partial 
response (PR), progressive disease and death. Patients enter the model after an assess-
ment of response to ﬁrst-line treatment (induction therapy) demonstrates partial or 
complete response. An important feature of the model is the possibility for response 
status to convert from PR to CR as shown in study 304,820. Following ﬁnal response, 
individuals either remain in their current health state, experience disease progression, 
or die. PFS data from the trial was used to model disease progression. Costs were 
calculated from the perspective of the Spanish health care system. Future costs and 
beneﬁts were discounted at 3.5% per annum. Utilities were calculated using the EQ-
5D from study 304,820. RESULTS: The incremental cost per additional QALY is 
estimated to be a18,263 for partial responders and a29,322 for all responders (includ-
ing those with a complete response after ﬁrst-line therapy). The parameters which 
have the greatest impact are the utility estimates, particularly the utility in the progres-
sion-free health state. CONCLUSIONS: The base case model demonstrates that 90Y-
ibritumomab tiuxetan consolidation following induction therapy offers good value for 
money while signiﬁcantly prolonging PFS. Sensitivity analyses show the results to be 
reasonably robust.
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OBJECTIVES: The 76 months follow-up of the BIG 1-98 study reported a hazard 
ratio [HR] for overall survival (OS) of 0.81 and a HR for disease free survival (DFS) 
of 0.84 in the letrozole (LET) group versus tamoxifene (TAM). The 100 months   
follow-up of the ATAC study reported almost identical results observed at 68 months 
follow-up for the HR of OS (0,97) in the anastrozole (ANA) group when compared 
with TAM. The HR for DFS was 0.85. This analysis compares the cost-effectiveness 
of LET and ANA versus tamoxifen from the Canadian health care perspective using 
the most recent survival data from the BIG 1-98 and ATAC studies. METHODS: A 
Markov model was used to estimate the cost per quality adjusted life year (QALY) of 
LET or ANA versus TAM. Annual survival probabilities were extracted from updated 
BIG 1-98 and ATAC trials, and literature. Cost values representing resource use were 
informed by a Canadian costing analysis. Utility weights were derived from literature. 
A time horizon of 20 years and a 5% discount rate were used. RESULTS: LET and 
ANA are predicted to increase QALYs by 0.26 and 0.05 per patient compared to 
TAM, respectively. Lifetime costs increase by $2710 and $2297 for LET and ANA 
respectively. The incremental cost-effectiveness ratio (ICER) of LET versus TAM is 
$10,420. The ICER for ANA versus TAM is $41,569. The model is more sensitive to 
the variation of the hazard ratios for overall survival. The probability that LET and 
ANA are cost-effective given a threshold value of 50,000 per QALY is 99% for LET 
and 58% for ANA. CONCLUSIONS: Our model shows that LET has a substantially 
lower expected ICER of $10,420 compared to ANA, with mean ICER of $41,569 
over a 20 year time horizon from the Canadian health care perspective.
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OBJECTIVES: Several new interventions have become available recently for the 
 adjuvant treatment of early breast cancer (EBC) which are effective in reducing 
the incidence of disease relapse. Our objective was to develop a model to evaluate the 
cost-effectiveness and cost-utility of such interventions in the USA. The model was 
demonstrated for the comparison of docetaxel (75 mg/m2), doxorubicin (50 mg/m2), 
and cyclophosphamide (500 mg/m2) (TAC, 6 cycles) with ﬂuorouracil (500 mg/m2), 
doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) (FAC, 6 cycles) in node-
positive EBC patients. METHODS: A combined decision tree and Markov model 
estimated costs and outcomes from initiation of adjuvant chemotherapy to death. 
Parametric survival functions were ﬁtted to patient-level data from trial BCIRG 001 
and time-dependent transition probabilities for disease relapse were estimated. Costs 
were estimated from US databases (Pharmetrics claims database and Premier hospital 
database) and a published retrospective analysis of linked SEER-Medicare data for 
1580 EBC patients with disease recurrence (cost year 2008). Utility weights were 
estimated from EORTC QLQ-C30 data collected in trial BCIRG 001 using a published 
algorithm, and from published literature. Probabilistic and univariate sensitivity analy-
sis (varying all parameters by / 50% of base-case values) were performed. Alterna-
tive scenarios were programmed to explore uncertainty beyond the trial follow-up 
period. RESULTS: Mean total expected lifetime costs and outcomes were signiﬁcantly 
higher for the TAC cohort. Incremental costs were $19,732 (95% CIs $15,869–
$31,441); life years were 0.93 (0.87–0.97) and QALYs were 0.74 (0.44–0.91). Incre-
mental cost-effectiveness ratios for TAC versus FAC were $21,318 per life year saved 
($16,953–$33,856) and $26,654 per QALY ($18,553–$50,554). In univariate sensi-
tivity analysis, results were most sensitive to the utility weight for remission post-
chemotherapy. The incremental cost per QALY remained below $50,000 for all 
plausible parameter estimates, and all extrapolation scenarios. CONCLUSIONS: The 
model provides a robust framework for estimating cost-effectiveness, allowing explo-
ration of critical areas of uncertainty.
PCN118
COST EFFECTIVENESS OF CETUXIMAB IN FIRST LINE TREATMENT  
OF METASTATIC COLORECTAL CANCER: DESCRIPTION OF A  
NICE SUBMISSION
Eggington SG1, Garrell D2, Griebsch I3, Samyshkin Y1
1IMS Health, London, UK, 2Merck Serono UK, Feltham, UK, 3Merck KGaA, Darmstadt, 
Germany
OBJECTIVES: To calculate the cost effectiveness of the addition of cetuximab to 
chemotherapy to enable resection of liver metastases in 1st-line metastatic colorectal 
cancer (mCRC) from the UK NHS perspective. METHODS: Cetuximab is licensed 
for the treatment of mCRC in combination with standard chemotherapy (FOLFIRI 
and FOLFOX) in patients with wildtype KRAS and EGFR expressing tumours. A semi 
Markov model was developed to simulate patient outcomes and costs throughout ﬁrst 
and subsequent lines of treatment including long-term survival after a successful cura-
tive resection of liver metastases. Data for model parameters were mainly derived the 
CRYSTAL and OPUS studies. The potential for curative-intent liver surgery was esti-
mated using resection rates from CELIM and Tournigand et al for cetuximab arms 
and chemotherapy arms respectively. The long-term beneﬁts of surgery were estimated 
from Adam et al. Extensive scenario and probabilistic sensitivity analyses were under-
taken to explore the robustness of the results with regard to various modelling 
assumptions and model parameter uncertainty. RESULTS: In the base case the addi-
tion of cetuximab to FOLFIRI/FOLFOX resulted in additional QALYs of 0.78 and 
0.59 and incremental cost effectiveness ratios (ICERs) of £19,557 and £21,056 per 
QALY respectively. The ICER is mainly driven by the number of patients becoming 
resectable, the acquisition cost of cetuximab, and choice of parametric model for 
progression-free survival curves. CONCLUSIONS: The analysis demonstrates that 
cetuximab is a cost-effective 1st line treatment option for patients with EGFR express-
ing, KRAS wildtype colorectal cancer, for patients whose liver metastases have been 
rendered resectable by cetuximab and. chemotherapy. This analysis resulted in positive 
draft guidance by NICE on June 1, 2009. Final Guidance will be posted on the NICE 
website in July 2009.
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OBJECTIVES: Approximately 8.33 years of randomized clinical trial data is now 
available from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, 
conﬁrming that the advantage of anastrozole in recurrence free survival compared 
with tamoxifen in hormone receptor-positive (HR) postmenopausal (PM) early breast 
cancer (EBC) patients is preserved even after stopping treatment at 5 years. Using the 
long-term outcome data, this study estimated the cost-utility of anastrozole versus 
